Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
The FDA announced on Friday that the shortage of semaglutide injection products like Novo Nordisk's Ozempic and Wegovy has been resolved. The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days.
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?
“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
Hims and Hers Stock Drops Weight as Earnings Loom
Hims & Hers Health Inc (NYSE:HIMS) stock has had a roller coaster week.
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved. The post Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage appeared first on Investor's Business Daily.
HIMS stock crashes 25% on Friday after this key FDA update
Shares of Hims & Hers Health plunged a massive 25% on Friday to hit an intraday low of around $49.01. The massive crash came after the US Food and Drug Administration (FDA) announced the end of the shortage of Novo Nordisk's weight-loss drugs.
Hims & Hers Health: The Ultimate Pick For The Next Decade
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. I provide multiple perspectives in this article, offering readers different viewpoints to draw their own conclusions. There are historical references, future valuations, and timeless investing lessons. There are five primary growth drivers that should continue to turbocharge HIMS' future revenue. I cover them all in detail.
Why Hims & Hers Stock Dropped Today
Hims & Hers Health (HIMS -4.55%) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed messages on the stock this morning.
Hims & Hers stock surges 23%: Telehealth company announces expansion into blood testing weeks after Super Bowl buzz
Amid a month of skyrocketing stock prices and unprecedented social media buzz, Hims & Hers Health is expanding its territory into at-home blood testing and diagnostics.
Atlanta Fed's Bostic, tariffs, Hims & Hers: Market Domination
Julie Hyman and Seana Smith are joined by key experts as take a closer look at the trending stories on Wall Street on Market Domination. Federal Reserve Bank of Atlanta president Raphael Bostic sits down with Yahoo Finance Senior Fed Reporter Jennifer Schonberger to discuss how the central bank is navigating its recent pause on interest rate hikes amid uncertainty around fiscal policy.
Hims & Hers Stock Hits Record High on Blood-Testing Lab Acquisition
Hims & Hers Health (HIMS) shares jumped roughly 20% to a fresh record high on Wednesday following the announcement that the company acquired lab testing facility Trybe Labs.
Why Hims & Hers Health Stock Is Skyrocketing Today
Shares of Hims & Hers Health Inc (HIMS 20.27%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m.
Hims & Hers to offer at-home blood draws and lab testing with new acquisition
Hims and Hers Health has acquired at-home lab testing facility Trybe Labs. The acquisition will allow the telehealth company to provide at-home lab testing through its platform.
